Development of a novel prolonged-release nicotine transdermal patch.

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Materials Science

Background:

• Transdermal drug delivery offers a non-invasive route for sustained medication administration.
• Nicotine replacement therapy (NRT) often requires controlled release for efficacy and patient compliance.
• Developing advanced patch formulations is crucial for optimizing transdermal drug delivery.

Purpose of the Study:

• To design and evaluate a novel transdermal patch for sustained nicotine delivery over 12-48 hours.
• To investigate the role of inclusion complexes and rate-controlling membranes in nicotine patch performance.
• To optimize patch composition for enhanced transdermal permeation and controlled release.

Main Methods:

• Formulation of nicotine inclusion complexes with beta-cyclodextrin (beta-CD).
• Utilizing cross-linked polyvinyl alcohol (cross-PVA) as a rate-controlling membrane.
• Investigating the impact of carbopol polymers (C-934P, C-940) and propylene glycol on nicotine permeation through rat skin.

Main Results:

• A maximum nicotine flux of 42 microg/cm²/h was achieved after 48 hours.
• Optimal performance was observed with C-934P carbopol, 15% propylene glycol, and a 3:1 nicotine-beta-CD mole ratio.
• The developed patches demonstrated potential for controlled, zero-order nicotine release.

Conclusions:

• The designed nicotine transdermal patches effectively deliver nicotine over extended periods (12-48h).
• Formulation parameters, including inclusion complex composition and polymer selection, significantly influence transdermal delivery.
• These patches represent a viable system for controlled, zero-order nicotine release, applicable to NRT.